Browsing tag:

Herceptin


The FDA made a historic move on September 12, 2013 with their nod to approve Pertuzumab, a monoclonal antibody (mAb), as a pre-surgical treatment for patients with early-stage metastatic breast cancer. Pertuzumab is currently approved as a treatment for women with late-stage breast cancer, but it is administered after surgery has been completed. This new[…]

Read More

Exemplary results in the 2012 Phase III trial coined EMILIA has led Roche Pharmaceuticals to initiate additional Phase III trials evaluating trastuzumab emtansine. The New Year brings registration trials for newly diagnosed as well as previously treated metastatic HER2-positive breast cancer patients. Trastuzumab will be evaluated in this 2013 study for three settings in earlier-stage[…]

Read More

J.R.Stokes Illustrations: Natural Killer: T-cell vs. Leukemia Researchers received encouraging news on March 22, 2012, with the information that the novel drug to treat acute lymphoblastic leukemia, known as Marqibo won an FDA panel vote. The group of oncology advisers voted 7-4 endorsing the Vincristine Sulfate CAS# 2068-78-2 liposomal injection, also known as the brand[…]

Read More

A study conducted by the Seoul National University College of Medicine, Seoul in South Korea found that the monoclonal antibody, Trastuzumab (Herceptin) used with chemotherapeutic drugs in the treatment of HER2-positive advanced gastroesophageal junction cancer showed a promising new treatment option for patients. HER2 protein is responsible for cell growth and division and the cell[…]

Read More